Literature DB >> 17655717

Comorbidity of migraine and headache associated with sexual activity.

K Biehl1, S Evers, A Frese.   

Abstract

In order to investigate the comorbidity of migraine and headache associated with sexual activity (HSA), we performed a case-control study based on migraine patients. By means of a questionnaire and a personal interview, 100 migraine patients and 100 control subjects were examined regarding a diagnosis of HSA. In five subjects from the migraine group vs. none from the control group, a diagnosis of HSA could be established (P = 0.021). Previous studies that have demonstrated comorbidity of migraine and HSA were all based on HSA patients. Thus, it can now be concluded that the association between the two headache disorders is bilateral. In addition, the prevalence of HSA in the general population can be estimated to average around at least 0.9%, which concurs with previously published data.

Entities:  

Mesh:

Year:  2007        PMID: 17655717     DOI: 10.1111/j.1468-2982.2007.01381.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  4 in total

1.  A not so happy ending: coital cephalgia resulting from an acute non-traumatic intraparenchymal haemorrhage in a female with no comorbidities.

Authors:  Hafez Mohammad Ammar Abdullah; Uzma Ikhtiar Khan; Ezza Tariq; Muhammad Omar
Journal:  BMJ Case Rep       Date:  2019-05-27

Review 2.  Focus on therapy of the Chapter IV headaches provoked by exertional factors: primary cough headache, primary exertional headache and primary headache associated with sexual activity.

Authors:  Marta Allena; Paolo Rossi; Cristina Tassorelli; Enrico Ferrante; Carlo Lisotto; Giuseppe Nappi
Journal:  J Headache Pain       Date:  2010-10-02       Impact factor: 7.277

3.  Other primary headaches.

Authors:  Anish Bahra
Journal:  Ann Indian Acad Neurol       Date:  2012-08       Impact factor: 1.383

4.  Other primary headaches-thunderclap-, cough-, exertional-, and sexual headache.

Authors:  Anish Bahra
Journal:  J Neurol       Date:  2020-03-04       Impact factor: 4.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.